HER-2 testing in breast cancer using parallel tissue-based methods
Article Abstract:
The HER-2 oncoprotein is overexpressed in 20% to 30% of invasive breast tumors, and its presence confers important prognostic information. Accurate testing for HER-2 in breast cancer can be achieved using immunohistochemistry with complementary fluorescence in situ hybridization (FISH) testing, taking advantage of the strength of each of these technologies.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
HER-2 testing in breast cancer using parallel tissue-based methods
Article Abstract:
The HER-2 oncoprotein is overexpressed in 20% to 30% of invasive breast tumors, and its presence confers important prognostic information. Accurate testing for HER-2 in breast cancer can be achieved using immunohistochemistry with complementary fluorescence in situ hybridization (FISH) testing, taking advantage of the strength of each of these technologies.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
High-quality HER-2 testing: setting a standard for oncologic biomaker assessment
Article Abstract:
The HER-2 proto-oncogene produces a cytoplasmic membrane, which indicates prognostic and predictive implications for patients with breast cancer. HER-2 can be measured at the gene or protein level in the clinical laboratory and tissue-based HER-2 testing is currently the standard.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Monoclonal antibody therapies shine in breast cancer clinical trials. Surgeons "vote with their feet" for sentinel node biopsy for breast cancer staging
- Abstracts: Participation in cancer clinical trials: race-, sex-, and age-based disparities. Clinical proteomics: personalized molecular medicine. (Linking Evidence and Experience)
- Abstracts: Harnessing brain signals shows promise for helping patients with paralysis. George Daley, MD, PhD, talks about the clinical promise of stem cell research
- Abstracts: Opioid prescriptions soar: Increase in legitimate use as well as abuse
- Abstracts: Harnessing brain signals shows promise for helping patients with paralysis. part 2 Growing role for umbilical cord blood